Consumer Health Education & Advocacy Training
BlueRipple Health equips you to understand your options for detecting, diagnosing, and treating coronary artery disease — and to advocate for yourself within a system that rewards proactivity.
Portal
The optimal balance between diagnostic accuracy, safety, and cost-effectiveness.
A fundamentally different approach to lowering LDL cholesterol.
The inherited risk factor most doctors never test for.
Banach et al., 2025 · Meta-analysis
Adding ezetimibe to a statin cut cardiovascular events and deaths beyond a statin alone — a combination that is cheap, generic, and underused.
Sehayek et al., 2025 · Systematic review
Across more than 590,000 people, apoB tracked cardiovascular risk more faithfully than LDL-C or non-HDL-C wherever the measures disagreed.
Ryan et al., 2024 · Prespecified analysis of randomized trial
In adults with obesity but not diabetes, semaglutide produced sustained weight loss across four years — without the rebound most diets bring.
The ACC mourns the loss of Robert L. Frye, MD, MACC, a distinguished physician, investigator, educator and leader whose career helped shape modern cardiovascular medicine, as well as the College. Frye, who served as ACC President from 1991-1992, leaves behind a legacy of service to patients and the profession spanning more than seven decades.
Read moreA long-term follow-up of the CENTRAL and DIRECT-PLUS trials published in Circulation suggests that despite long-term weight regain, visceral fat reduction during lifestyle intervention is associated with sustained improvements in metabolic health.
Read moreGet annual access to the Portal — a comprehensive, independent analysis of every option available for coronary artery disease.
Get Annual Access — $199/yr